Pharmacodynamic effects of daclizumab in the intrathecal compartment

OBJECTIVE: It was previously demonstrated that daclizumab therapy normalizes cellular cerebrospinal fluid (CSF) abnormalities typical of multiple sclerosis (MS) in the majority of treated patients. However, CSF cells represent only the mobile portion of intrathecal immune responses. Therefore, we as...

Descripción completa

Detalles Bibliográficos
Autores principales: Komori, Mika, Kosa, Peter, Stein, Jason, Zhao, Vivian, Blake, Andrew, Cherup, Jamie, Sheridan, James, Wu, Tianxia, Bielekova, Bibiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497534/
https://www.ncbi.nlm.nih.gov/pubmed/28695148
http://dx.doi.org/10.1002/acn3.427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497534/
https://www.ncbi.nlm.nih.gov/pubmed/28695148
http://dx.doi.org/10.1002/acn3.427

Ejemplares similares